According to the disclosure of the semi-annual report for 2024 by Porton Pharma Solutions (300363.SZ), the company achieved a revenue of 1.352 billion yuan during the reporting period, a year-on-year decrease of 42.19%. The net loss attributable to shareholders of the listed company was 0.17 billion yuan, and the net loss attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.174 billion yuan, which changed from profit to loss compared to the same period last year.